Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned ...

Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...

Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era ...

Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

WuXi AppTec’s revenue rose for the first few months of 2025, signaling that pressures from the proposed Biosecure Act may be ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...